Hamlet Hassan, MD
Psychiatry · Miami, FLNPI 1326128323
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,631 of the $2,447 with a category attached, or 66.6%. 10 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 46.7% of the total. 2025 is the largest year on record at $1,167, 4.4 times the $267 reported in 2019.
Across 64 payments — averaging $38.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$404
- Otsuka America Pharmaceutical, Inc.$338
- Sunovion Pharmaceuticals Inc.$140
- Teva Pharmaceuticals USA, Inc.$140
- Axsome Therapeutics, Inc.$114
- plus $167 from 4 others
Across 73 payments — averaging $10,946 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Avanir Pharmaceuticals, Inc.$331K
- Janssen Research & Development, LLC$171K
- Eli Lilly$159K
- Teva Pharmaceuticals USA, Inc.$69K
- AbbVie$68K
What the payments were for
- Travel & lodging$81333%
- Food & beverage$1,63167%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 8 | $1,144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $404 |
| Otsuka America Pharmaceutical, Inc. | 7 | $338 |
| Sunovion Pharmaceuticals Inc. | 8 | $140 |
| Teva Pharmaceuticals USA, Inc. | 9 | $140 |
| Axsome Therapeutics, Inc. | 5 | $114 |
| AbbVie(2 entities) | 5 | $79 |
| Lundbeck LLC | 2 | $40 |
| Johnson & Johnson | 2 | $34 |
| Tempus AI, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$125
- ABILIFY MAINTENA$120
How this compares
$2,447 in reported general payments places this provider in the 75th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 215 | $86,562 |
| TrintellixVortioxetine Hydrobromide | 96 | $46,398 |
| Invega SustennaPaliperidone Palmitate | 14 | $37,356 |
| Mirtazapine | 1,632 | $36,052 |
| Olanzapine | 382 | $25,396 |
| AuvelityDextromethorphan Hbr/Bupropion | 20 | $21,374 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 50 | $19,375 |
| Duloxetine Hcl | 395 | $14,333 |
| Quetiapine Fumarate | 1,296 | $13,706 |
| Fluoxetine Hcl | 471 | $13,463 |
| Escitalopram Oxalate | 2,339 | $10,129 |
| Memantine Hcl ErMemantine Hcl | 50 | $9,563 |
| Triazolam | 164 | $9,077 |
| Temazepam | 1,424 | $7,433 |
| Clonazepam | 1,037 | $7,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $404 | $46,39896 claims |
| Johnson & JohnsonInvega Sustenna | $34 | $37,35614 claims |
| Axsome Therapeutics, Inc.Auvelity | $114 | $21,37420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Miami
- Kenny PerezMiami$453K
- Erik CabreraMiami$357K
- Miguel FloresMiami$176K
- Pedro RodriguezMiami$96K
- John NewcomerMiami$96K
- Patricia JunqueraMiami$80K
- Marc AgroninMiami$66K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.